• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/18/21 10:49:05 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HEPA alert in real time by email
    SC 13G 1 p21-0764sc13g.htm HEPION PHARMACEUTICALS, INC.

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.   )*
     

    Hepion Pharmaceuticals, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001

    (Title of Class of Securities)
     

    426897104

    (CUSIP Number)
     

    February 16, 2021

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 10 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 426897104

    13G

    Page 2 of 10 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Empery Asset Management, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,000,000 shares of Common Stock

    335,745 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

    4,945 shares of Common Stock issuable upon exercise of Warrants

     

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,000,000 shares of Common Stock

    335,745 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

    4,945 shares of Common Stock issuable upon exercise of Warrants

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,000,000 shares of Common Stock

    335,745 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

    4,945 shares of Common Stock issuable upon exercise of Warrants

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.25% (See Item 4)*

    12

    TYPE OF REPORTING PERSON

    PN

             

     

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    CUSIP No. 426897104

    13G

    Page 3 of 10 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Ryan M. Lane

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,000,000 shares of Common Stock

    335,745 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

    4,945 shares of Common Stock issuable upon exercise of Warrants

     

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,000,000 shares of Common Stock

    335,745 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

    4,945 shares of Common Stock issuable upon exercise of Warrants

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,000,000 shares of Common Stock

    335,745 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

    4,945 shares of Common Stock issuable upon exercise of Warrants

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.25% (See Item 4)*

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

     

    CUSIP No. 426897104

    13G

    Page 4 of 10 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Martin D. Hoe

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,000,000 shares of Common Stock

    335,745 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

    4,945 shares of Common Stock issuable upon exercise of Warrants

     

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,000,000 shares of Common Stock

    335,745 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

    4,945 shares of Common Stock issuable upon exercise of Warrants

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,000,000 shares of Common Stock

    335,745 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

    4,945 shares of Common Stock issuable upon exercise of Warrants

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.25% (See Item 4)*

    12

    TYPE OF REPORTING PERSON

    IN

             

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    CUSIP No. 426897104

    13G

    Page 5 of 10 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Hepion Pharmaceuticals, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 399 Thornall Street, First Floor, Edison, New Jersey 08837.

     

    Item 2(a). NAME OF PERSON FILING:

     

     

    This statement is filed by the entities and persons listed below, who are collectively referred to herein as "Reporting Persons," with respect to the Common Stock (as defined in Item 2(d) below) of the Company:

     

    Investment Manager

     

    (i)       Empery Asset Management, LP (the "Investment Manager"), with respect to the shares of Common Stock held by, and underlying the Reported Warrants (as defined below) held by, funds to which the Investment Manager serves as investment manager (the "Empery Funds").

     

    Reporting Individuals

     

    (ii)       Mr. Ryan M. Lane ("Mr. Lane"), with respect to the shares of Common Stock held by, and underlying the Reported Warrants held by, the Empery Funds.

     

    (iii)       Mr. Martin D. Hoe ("Mr. Hoe"), with respect to the shares of Common Stock held by, and underlying the Reported Warrants held by, the Empery Funds.

     

    The Investment Manager serves as the investment manager to each of the Empery Funds. Each of Mr. Lane and Mr. Hoe (the "Reporting Individuals") is a Managing Member of Empery AM GP, LLC (the "General Partner"), the general partner of the Investment Manager.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

     

    The address of the business office of each of the Reporting Persons is:

     

    1 Rockefeller Plaza, Suite 1205

    New York, New York 10020

     

    Item 2(c). CITIZENSHIP:

     

      Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    CUSIP No. 426897104

    13G

    Page 6 of 10 Pages

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.0001 (the "Common Stock")

     

    Item 2(e). CUSIP NUMBER:
       
      426897104

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
      (e) ¨ Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940,
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
      (g) ¨ Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
      (i) ¨ Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940,
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:____________________________

     

    CUSIP No. 426897104

    13G

    Page 7 of 10 Pages

     

    Item 4. OWNERSHIP.

     

       

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 76,225,153 shares of Common Stock issued and outstanding as of February 16, 2021, as represented in the Company’s Prospectus Supplement on Form 424(b)(5) filed with the Securities and Exchange Commission on February 16, 2021 and assumes the exercise of the Company’s reported warrants (the “Reported Warrants”) subject to the Blockers (as defined below).

     

    Pursuant to the terms of the Reported Warrants, the Reporting Persons cannot exercise the Reported Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding shares of Common Stock (the "Blockers"), and the percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Blockers. Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise all of the Reported Warrants due to the Blockers.

     

    The Investment Manager, which serves as the investment manager to the Empery Funds, may be deemed to be the beneficial owner of all shares of Common Stock held by, and underlying the Reported Warrants (subject to the Blockers) held by, the Empery Funds. Each of the Reporting Individuals, as Managing Members of the General Partner of the Investment Manager with the power to exercise investment discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by, and underlying the Reported Warrants (subject to the Blockers) held by, the Empery Funds. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person. Each of the Empery Funds and the Reporting Individuals hereby disclaims any beneficial ownership of any such shares of Common Stock.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
      See Item 2(a) above.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
      Not applicable.

     

    CUSIP No. 426897104

    13G

    Page 8 of 10 Pages

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    CUSIP No. 426897104

    13G

    Page 9 of 10 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: February 18, 2021

     

      EMPERY ASSET MANAGEMENT, LP
      By: EMPERY AM GP, LLC, its General Partner
       
      By: /s/ Ryan M. Lane
      Name:  Ryan M. Lane
      Title:  Managing Member
       
      /s/ Ryan M. Lane
      Ryan M. Lane
       
      /s/ Martin D. Hoe
      Martin D. Hoe

     

     

    CUSIP No. 426897104

    13G

    Page 10 of 10 Pages

     

    EXHIBIT 1

    JOINT ACQUISITION STATEMENT
    PURSUANT TO RULE 13d-1(k)

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

    DATED: February 18, 2021

     

      EMPERY ASSET MANAGEMENT, LP
      By: EMPERY AM GP, LLC, its General Partner
       
      By: /s/ Ryan M. Lane
      Name:  Ryan M. Lane
      Title:  Managing Member
       
      /s/ Ryan M. Lane
      Ryan M. Lane
       
      /s/ Martin D. Hoe
      Martin D. Hoe

     

    Get the next $HEPA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HEPA

    DatePrice TargetRatingAnalyst
    2/28/2022$3.50Overweight
    Cantor Fitzgerald
    More analyst ratings

    $HEPA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Hepion Pharmaceuticals Inc.

      10-Q - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)

      5/19/25 5:30:01 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Hepion Pharmaceuticals Inc.

      SCHEDULE 13G - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

      5/15/25 5:23:33 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-Q filed by Hepion Pharmaceuticals Inc.

      NT 10-Q - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)

      5/15/25 4:30:28 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HEPA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Hepion Pharmaceuticals with a new price target

      Cantor Fitzgerald initiated coverage of Hepion Pharmaceuticals with a rating of Overweight and set a new price target of $3.50

      2/28/22 8:01:07 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HEPA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Purcell Michael J.

      4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

      3/7/24 4:15:14 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Purcell Michael J.

      3 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

      3/6/24 4:30:41 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Jacob Gary S

      4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

      2/21/24 8:01:44 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HEPA
    Leadership Updates

    Live Leadership Updates

    See more

    $HEPA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

      EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, and other chronic diseases, today announced the appointment of Michael Purcell to the Company's Board of Directors, effective March 5, 2024. Mr. Purcell has more than 37 years of professional experience with Deloitte & Touche LLP, serving as a consultant from 2015 to 2017 and an Audit Partner from 1979 until 2015. Mr. Purcell also currently serves as a financial advisor to several emerging growth companies. Mr. Purcell is a certified p

      3/6/24 8:30:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theralase(R) Announces Appointment of New Independent Director

      TORONTO, ON / ACCESSWIRE / June 6, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, is pleased to announce the appointment of new independent director, Kaouthar Lbiati, M.D., M.Sc. Dr. Lbiati received her Doctor of Medicine from Rabat, Morocco's Mohammed V University and a post-doctorate in clinical oncology from Gustave Roussy Institute in Paris, which is a premier European cancer center and one o

      6/6/23 7:00:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati

      EDISON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and hepatocellular carcinoma ("HCC"), today announced the appointments of Anand Reddi, M.S., and Kaouthar Lbiati, M.D., to its Board of Directors, effective immediately. "We are thrilled to welcome individuals of this caliber to our Board," said Hepion's Chairman, Gary S. Jacob, Ph.D. "Mr. Reddi and Dr. Lbiati have a remarkable wealth of experience across all aspects of drug development, from clinical research to med

      6/28/22 8:30:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wijngaard Peter bought $15,350 worth of shares (5,000 units at $3.07), increasing direct ownership by 111% to 9,501 units (SEC Form 4)

      4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

      11/28/23 6:55:05 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Wijngaard Peter bought $16,841 worth of shares (3,000 units at $5.61), increasing direct ownership by 200% to 4,501 units

      4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

      9/20/23 11:27:22 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Foster Robert T bought $8,960 worth of shares (1,600 units at $5.60), increasing direct ownership by 3% to 50,470 units

      4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

      9/19/23 9:01:30 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HEPA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

      MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases which has transitioned to a developer and distributor of diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), H. pylori and HCC, today announced that on May 9, 2025, the Company received written notice (the "Notice") from the Office of General Counsel of The Nasdaq Stock Market ("Nasdaq") indicating that the Nasdaq Hearings Panel has determined to delist the Company's shar

      5/12/25 4:30:00 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC

      MORRISTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases, today announced that it has entered into a binding letter of intent ("LOI") with New Day Diagnostics LLC to in-license diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC). The celiac, respiratory multiplex and H. pylori tests have CE marks and are eligible to be sold in Europe at the present time. The di

      5/7/25 8:30:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hepion Pharmaceuticals Announces Reverse Stock Split

      Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025 MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases, today announced that it will implement a 1-for-50 reverse split of the issued shares of its common stock, effective at 4:01 p.m. Eastern Time on March 17, 2025. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on March 18, 2025, and will continue to trade on The Nasdaq Capital

      3/14/25 8:30:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HEPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Hepion Pharmaceuticals Inc.

      SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

      11/14/24 4:07:59 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Hepion Pharmaceuticals Inc.

      SC 13G - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

      2/14/24 3:38:57 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Hepion Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

      2/14/22 6:05:01 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HEPA
    Financials

    Live finance-specific insights

    See more
    • Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease

      - Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease biomarkers and HepQuant Duo liver function test - "These findings presented today at AASLD The Liver Meeting® confirm that rencofilstat's novel mechanism of action represents a fresh approach to the treatment of severe liver disease." (Patrick Mayo, PhD, Hepion's Senior VP, Clinical Pharmacology & Analytics) EDISON, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the t

      11/13/23 4:05:00 PM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 'ALTITUDE-NASH' Liver Function Trial of Rencofilstat

      EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced that it expects to release additional efficacy data from the Phase 2 ALTITUDE-NASH clinical trial of its lead drug, rencofilstat, after market close on Monday, November 13, 2023. The data release will follow a late-breaker poster presentation by Hepion's Senior Vice President, Clinical Pharmacology, Patrick Mayo, PhD, at the

      11/10/23 8:50:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hepion Pharmaceuticals' Phase 2 'ALTITUDE-NASH' Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers

      - Improvements in physiologic liver function and key NASH biomarkers including ALT, ProC3, PIIINP and ELF - - Results reinforce rencofilstat's direct antifibrotic mode of action; increases confidence for reductions in fibrosis in ongoing Phase 2b ‘ASCEND-NASH' paired biopsy trial - EDISON, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial Intelligence ("AI")-assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced positive topline results from its recentl

      5/22/23 7:00:00 AM ET
      $HEPA
      Biotechnology: Pharmaceutical Preparations
      Health Care